{"pmid":32348715,"title":"B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020.","text":["B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020.","Viral Immunol","Hurwitz, Julia L","32348715"],"journal":"Viral Immunol","authors":["Hurwitz, Julia L"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348715","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1089/vim.2020.0055","topics":["Mechanism"],"weight":1,"_version_":1665441658190168064,"score":8.599203,"similar":[{"pmid":32303698,"title":"A map of SARS-CoV-2 and host cell interactions.","text":["A map of SARS-CoV-2 and host cell interactions.","Nat Rev Immunol","Malle, Louise","32303698"],"journal":"Nat Rev Immunol","authors":["Malle, Louise"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303698","week":"202016|Apr 13 - Apr 19","doi":"10.1038/s41577-020-0318-1","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664632934641958913,"score":53.279346},{"pmid":32165541,"pmcid":"PMC7132130","title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.","text":["Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.","A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused a large respiratory outbreak in Wuhan, China in December 2019, is currently spreading across many countries globally. Here, we show that a TMPRSS2-expressing VeroE6 cell line is highly susceptible to SARS-CoV-2 infection, making it useful for isolating and propagating SARS-CoV-2. Our results reveal that, in common with SARS- and Middle East respiratory syndrome-CoV, SARS-CoV-2 infection is enhanced by TMPRSS2.","Proc Natl Acad Sci U S A","Matsuyama, Shutoku","Nao, Naganori","Shirato, Kazuya","Kawase, Miyuki","Saito, Shinji","Takayama, Ikuyo","Nagata, Noriyo","Sekizuka, Tsuyoshi","Katoh, Hiroshi","Kato, Fumihiro","Sakata, Masafumi","Tahara, Maino","Kutsuna, Satoshi","Ohmagari, Norio","Kuroda, Makoto","Suzuki, Tadaki","Kageyama, Tsutomu","Takeda, Makoto","32165541"],"abstract":["A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused a large respiratory outbreak in Wuhan, China in December 2019, is currently spreading across many countries globally. Here, we show that a TMPRSS2-expressing VeroE6 cell line is highly susceptible to SARS-CoV-2 infection, making it useful for isolating and propagating SARS-CoV-2. Our results reveal that, in common with SARS- and Middle East respiratory syndrome-CoV, SARS-CoV-2 infection is enhanced by TMPRSS2."],"journal":"Proc Natl Acad Sci U S A","authors":["Matsuyama, Shutoku","Nao, Naganori","Shirato, Kazuya","Kawase, Miyuki","Saito, Shinji","Takayama, Ikuyo","Nagata, Noriyo","Sekizuka, Tsuyoshi","Katoh, Hiroshi","Kato, Fumihiro","Sakata, Masafumi","Tahara, Maino","Kutsuna, Satoshi","Ohmagari, Norio","Kuroda, Makoto","Suzuki, Tadaki","Kageyama, Tsutomu","Takeda, Makoto"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32165541","week":"202011|Mar 09 - Mar 15","doi":"10.1073/pnas.2002589117","keywords":["sars-cov-2","tmprss2","veroe6","coronavirus","outbreak"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874758275073,"score":53.279346},{"pmid":32289117,"pmcid":"PMC7144842","title":"Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.","text":["Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.","A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called \"I-cells\". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for \"off-the-shelf\" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.","Med Drug Discov","Ji, Henry","Yan, Ying","Ding, Beibei","Guo, Wenzhong","Brunswick, Mark","Niethammer, Andreas","SooHoo, Williams","Smith, Robin","Nahama, Alexis","Zhang, Yanliang","32289117"],"abstract":["A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called \"I-cells\". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for \"off-the-shelf\" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease."],"journal":"Med Drug Discov","authors":["Ji, Henry","Yan, Ying","Ding, Beibei","Guo, Wenzhong","Brunswick, Mark","Niethammer, Andreas","SooHoo, Williams","Smith, Robin","Nahama, Alexis","Zhang, Yanliang"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289117","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.medidd.2020.100026","keywords":["antigen","covid-19","coronavirus","sars-cov-2","transgenic cell vaccination","vaccine"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664636391697416193,"score":49.92622},{"pmid":32130973,"pmcid":"PMC7114098","title":"A potential role for integrins in host cell entry by SARS-CoV-2.","text":["A potential role for integrins in host cell entry by SARS-CoV-2.","Antiviral Res","Sigrist, Christian Ja","Bridge, Alan","Le Mercier, Philippe","32130973"],"journal":"Antiviral Res","authors":["Sigrist, Christian Ja","Bridge, Alan","Le Mercier, Philippe"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32130973","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.antiviral.2020.104759","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664640874983718913,"score":49.88515},{"pmid":32340551,"title":"Natural products may interfere with SARS-CoV-2 attachment to the host cell.","text":["Natural products may interfere with SARS-CoV-2 attachment to the host cell.","Objectives: SARS-CoV-2 has been emerged in December 2019 in China, causing deadly (5% mortality) pandemic pneumonia, termed COVID-19. More than one host-cell receptor is reported to be recognized by the viral spike protein, among them is the cell-surface Heat Shock Protein A5 (HSPA5), also termed GRP78 or BiP. Upon viral infection, HSPA5 is upregulated, then translocating to the cell membrane where it is subjected to be recognized by the SARS-CoV-2 spike. In this study, some natural product compounds are tested against the HSPA5 substrate-binding domain beta (SBDbeta), which reported to be the recognition site for the SARS-CoV-2 spike.Methods: Molecular docking and molecular dynamics simulations are used to test some natural compounds binding to HSPA5 SBDbeta.Results: The results show high to a moderate binding affinity for the phytoestrogens (Diadiazin, Genistein, Formontein, and Biochanin A), chlorogenic acid, linolenic acid, palmitic acid, caffeic acid, caffeic acid phenethyl ester, hydroxytyrosol, cis-p-Coumaric acid, cinnamaldehyde, thymoquinone, and some physiological hormones such as estrogens, progesterone, testosterone, and cholesterol to the HSPA5 SBDbeta. Based on its binding affinities, the phytoestrogens and estrogens are the best in binding HSPA5, hence may interfere with SARS-CoV-2 attachment to the stressed cells.Conclusion: These compounds can be successful as anti-COVID-19 agents for people with a high risk of cell stress like elders, cancer patients, and front-line medical staff.","J Biomol Struct Dyn","Elfiky, Abdo A","32340551"],"abstract":["Objectives: SARS-CoV-2 has been emerged in December 2019 in China, causing deadly (5% mortality) pandemic pneumonia, termed COVID-19. More than one host-cell receptor is reported to be recognized by the viral spike protein, among them is the cell-surface Heat Shock Protein A5 (HSPA5), also termed GRP78 or BiP. Upon viral infection, HSPA5 is upregulated, then translocating to the cell membrane where it is subjected to be recognized by the SARS-CoV-2 spike. In this study, some natural product compounds are tested against the HSPA5 substrate-binding domain beta (SBDbeta), which reported to be the recognition site for the SARS-CoV-2 spike.Methods: Molecular docking and molecular dynamics simulations are used to test some natural compounds binding to HSPA5 SBDbeta.Results: The results show high to a moderate binding affinity for the phytoestrogens (Diadiazin, Genistein, Formontein, and Biochanin A), chlorogenic acid, linolenic acid, palmitic acid, caffeic acid, caffeic acid phenethyl ester, hydroxytyrosol, cis-p-Coumaric acid, cinnamaldehyde, thymoquinone, and some physiological hormones such as estrogens, progesterone, testosterone, and cholesterol to the HSPA5 SBDbeta. Based on its binding affinities, the phytoestrogens and estrogens are the best in binding HSPA5, hence may interfere with SARS-CoV-2 attachment to the stressed cells.Conclusion: These compounds can be successful as anti-COVID-19 agents for people with a high risk of cell stress like elders, cancer patients, and front-line medical staff."],"journal":"J Biomol Struct Dyn","authors":["Elfiky, Abdo A"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340551","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1080/07391102.2020.1761881","keywords":["covid-19","grp78","hspa5","molecular dynamics simulation","natural compounds","peptide-protein docking"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Testosterone","Genistein","Palmitic Acid","3,4-dihydroxyphenylethanol","Cholesterol","Chlorogenic Acid","Progesterone","caffeic acid phenethyl ester","caffeic acid","cinnamic aldehyde","alpha-Linolenic Acid","thymoquinone"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1665351883971100672,"score":49.88515}]}